Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Regulation of actin cytoskeleton (mmu04810)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
2900073G
15Rik
KLA  ATP  ATP+KLA
 NM_026064 RIKEN cDNA 2900073G15 gene (2900073G15Rik), mRNA [NM_026064] KLA 1.50 1.46 1.64 1.51 1.69 1.72 1.15
ATP 1.05 1.10 1.24 1.39 1.23 1.13 1.03
KLA/ATP 1.50 1.60 1.64 1.71 1.36 1.21 1.11
6720456B
07Rik
KLA  ATP  ATP+KLA
 NM_133937 RIKEN cDNA 6720456B07 gene (6720456B07Rik), mRNA [NM_133937] KLA .68 .67 .68 .68 .73 .80 .82
ATP .93 .91 1.26 1.13 1.00 .96 .71
KLA/ATP .65 .67 .87 .78 .96 .81 .67
AK044953
KLA  ATP  ATP+KLA
 AK044953 9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130015K01 product:unclassifiable, full insert sequence. [AK044953] KLA .54 .53 .47 .57 .61 .59 .60
ATP 1.02 .94 1.06 .95 .53 .55 .73
KLA/ATP .54 .47 .60 .67 .66 .49 .50
AK054191
KLA  ATP  ATP+KLA
 AK054191 2 days pregnant adult female oviduct cDNA, RIKEN full-length enriched library, clone:E230026L21 product:unclassifiable, full insert sequence. [AK054191] KLA .93 .86 .87 .83 1.34 .98 1.01
ATP .82 .56 .40 .62 1.44 1.24 1.14
KLA/ATP .86 .51 .40 .73 1.35 .98 1.14
Abi2
KLA  ATP  ATP+KLA
 NM_198127 abl-interactor 2 (Abi2), mRNA [NM_198127] KLA .83 .75 .72 .71 .69 .56 .60
ATP 1.11 1.11 1.01 .91 .83 .80 .74
KLA/ATP .78 .81 .70 .69 .69 .65 .55
Actb
KLA  ATP  ATP+KLA
 BC016624 cDNA clone IMAGE:4501052 [BC016624] KLA 1.20 1.20 1.19 1.73 1.83 2.52 1.70
ATP 1.04 1.01 1.03 .92 1.07 .66 .91
KLA/ATP 1.34 1.40 1.69 1.28 1.27 1.19 1.06
Actb
KLA  ATP  ATP+KLA
 NM_007393 actin, beta, cytoplasmic (Actb), mRNA [NM_007393] KLA 1.58 1.64 1.59 2.02 2.03 3.04 1.75
ATP 1.00 .95 1.26 1.18 1.33 .86 .91
KLA/ATP 1.52 1.75 2.42 1.92 2.17 1.54 1.28
Actg1
KLA  ATP  ATP+KLA
 NM_009609 actin, gamma, cytoplasmic 1 (Actg1), mRNA [NM_009609] KLA 1.02 1.03 1.34 1.07 1.49 1.58 .71
ATP 1.07 1.24 .76 .76 .63 .46 .78
KLA/ATP 1.20 1.30 .75 .82 .60 .53 .55
Actn1
KLA  ATP  ATP+KLA
 NM_134156 actinin, alpha 1 (Actn1), mRNA [NM_134156] KLA 1.33 1.42 1.46 1.16 1.18 .69 .54
ATP 1.06 1.13 .67 1.15 .95 .99 1.46
KLA/ATP 1.66 1.64 .81 1.55 .82 .78 .76
Actn2
KLA  ATP  ATP+KLA
 NM_033268 actinin alpha 2 (Actn2), mRNA [NM_033268] KLA 1.03 .94 1.02 1.05 1.02 1.06 1.11
ATP 1.04 .98 1.07 .99 1.10 1.03 1.02
KLA/ATP 1.06 1.03 .99 1.08 1.01 1.05 .98
Actn3
KLA  ATP  ATP+KLA
 NM_013456 actinin alpha 3 (Actn3), mRNA [NM_013456] KLA .97 .98 .98 .94 1.03 .96 1.07
ATP .95 .95 1.02 .98 .94 .95 1.01
KLA/ATP 1.05 1.03 .94 1.03 1.03 1.00 .95
Actn4
KLA  ATP  ATP+KLA
 NM_021895 actinin alpha 4 (Actn4), mRNA [NM_021895] KLA .78 .77 .75 .74 .58 .51 .65
ATP 1.03 1.03 1.21 1.14 1.50 1.30 1.09
KLA/ATP .78 .85 .96 .84 1.09 1.12 .97
Apc
KLA  ATP  ATP+KLA
 NM_007462 adenomatosis polyposis coli (Apc), mRNA [NM_007462] KLA .98 .94 .91 .86 .83 .91 1.01
ATP 1.06 1.16 1.04 .97 1.63 1.50 1.25
KLA/ATP 1.01 1.01 .92 .88 1.22 1.46 1.21
Apc2
KLA  ATP  ATP+KLA
 NM_011789 adenomatosis polyposis coli 2 (Apc2), mRNA [NM_011789] KLA 1.05 1.15 1.12 1.13 1.07 1.11 1.08
ATP 1.04 .97 1.15 1.27 1.12 1.09 1.16
KLA/ATP 1.12 1.20 1.21 1.24 1.25 1.13 1.04
Araf
KLA  ATP  ATP+KLA
 NM_009703 v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] KLA .87 .80 .89 .93 1.10 1.19 1.16
ATP 1.09 1.11 1.19 1.18 .78 .53 1.18
KLA/ATP 1.00 .95 .99 .93 .63 .55 1.27
Arhgef1
KLA  ATP  ATP+KLA
 NM_008488 Rho guanine nucleotide exchange factor (GEF) 1 (Arhgef1), mRNA [NM_008488] KLA .80 .82 .80 .56 .66 .74 .85
ATP 1.19 1.53 .87 1.47 .87 .55 .84
KLA/ATP 1.07 .88 .51 .99 .50 .58 .65
Arhgef12
KLA  ATP  ATP+KLA
 NM_027144 Rho guanine nucleotide exchange factor (GEF) 12 (Arhgef12), mRNA [NM_027144] KLA 1.01 .94 .89 .87 .84 .81 .80
ATP 1.05 .94 1.09 .77 .60 .86 .78
KLA/ATP .93 .88 .86 .70 .52 .66 .58
Arhgef4
KLA  ATP  ATP+KLA
 NM_183019 Rho guanine nucleotide exchange factor (GEF) 4 (Arhgef4), mRNA [NM_183019] KLA .37 .38 .38 .39 .39 .39 .39
ATP 1.05 .95 .82 .61 .57 .37 .39
KLA/ATP .40 .39 .44 .41 .61 .37 .32
Arhgef6
KLA  ATP  ATP+KLA
 AK028642 10 days neonate skin cDNA, RIKEN full-length enriched library, clone:4732422I02 product:Rac/Cdc42 guanine exchange factor (GEF) 6, full insert sequence. [AK028642] KLA .55 .52 .59 .60 .69 .61 .60
ATP 1.29 1.30 .63 .50 .76 .62 .74
KLA/ATP .54 .52 .70 .61 .67 .50 .55
Arhgef6
KLA  ATP  ATP+KLA
 NM_152801 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 (Arhgef6), mRNA [NM_152801] KLA .61 .64 .55 .52 .44 .37 .52
ATP 1.06 1.01 .97 1.02 .77 .58 .89
KLA/ATP .67 .65 .53 .58 .49 .43 .49
Arhgef7
KLA  ATP  ATP+KLA
 NM_001113517 Rho guanine nucleotide exchange factor (GEF7) (Arhgef7), transcript variant 1, mRNA [NM_001113517] KLA .54 .56 .63 .69 .58 .59 .49
ATP 1.58 2.80 1.54 .84 .56 .63 .75
KLA/ATP .68 .84 .87 .62 .54 .56 .54
Arhgef7
KLA  ATP  ATP+KLA
 NM_017402 Rho guanine nucleotide exchange factor (GEF7) (Arhgef7), transcript variant 3, mRNA [NM_017402] KLA .25 .23 .30 .29 .40 .44 .43
ATP 1.18 1.23 .82 1.11 .39 .28 .61
KLA/ATP .30 .26 .21 .28 .19 .27 .45
Arpc1a
KLA  ATP  ATP+KLA
 NM_019767 actin related protein 2/3 complex, subunit 1A (Arpc1a), mRNA [NM_019767] KLA .80 .78 .73 .79 .90 1.02 .97
ATP 1.01 1.07 .93 .86 .83 1.14 1.15
KLA/ATP .77 .74 .64 .64 .77 1.13 1.51
Arpc1b
KLA  ATP  ATP+KLA
 NM_023142 actin related protein 2/3 complex, subunit 1B (Arpc1b), mRNA [NM_023142] KLA .85 .86 .81 .83 .92 .93 1.03
ATP 1.03 .98 .86 .79 .84 .85 .91
KLA/ATP .88 .84 .83 .73 .71 .70 .63
Arpc2
KLA  ATP  ATP+KLA
 NM_029711 actin related protein 2/3 complex, subunit 2 (Arpc2), mRNA [NM_029711] KLA .88 .89 1.05 .92 1.18 1.31 1.21
ATP 1.20 1.18 .86 .94 .85 .48 .87
KLA/ATP 1.04 1.05 .78 .87 .70 .60 .92
Arpc3
KLA  ATP  ATP+KLA
 NM_019824 actin related protein 2/3 complex, subunit 3 (Arpc3), mRNA [NM_019824] KLA .93 .96 1.05 .95 1.07 1.09 .80
ATP 1.08 1.05 .95 .99 1.03 1.01 .97
KLA/ATP 1.00 1.02 .99 1.04 1.06 1.21 .99
Arpc4
KLA  ATP  ATP+KLA
 NM_026552 actin related protein 2/3 complex, subunit 4 (Arpc4), mRNA [NM_026552] KLA .75 .81 .83 .73 .94 1.12 1.12
ATP 1.09 1.34 .90 1.52 .98 .63 .89
KLA/ATP .92 .90 .58 1.10 .64 .69 .87
Arpc5
KLA  ATP  ATP+KLA
 NM_026369 actin related protein 2/3 complex, subunit 5 (Arpc5), mRNA [NM_026369] KLA 1.35 1.37 1.44 1.33 1.59 1.84 1.39
ATP .98 1.08 1.01 1.14 .97 .87 1.36
KLA/ATP 1.19 1.30 1.23 1.44 1.13 1.28 1.60
Arpc5l
KLA  ATP  ATP+KLA
 NM_028809 actin related protein 2/3 complex, subunit 5-like (Arpc5l), mRNA [NM_028809] KLA .59 .61 .60 .59 .61 .77 1.02
ATP .92 .92 .99 1.01 .79 .76 1.01
KLA/ATP .58 .60 .64 .59 .66 .71 .98
BC010335
KLA  ATP  ATP+KLA
 BC010335 fibronectin 1, mRNA (cDNA clone IMAGE:3156499), **** WARNING: chimeric clone ****. [BC010335] KLA .94 .88 1.01 .99 .95 .95 1.07
ATP 1.06 .98 1.20 1.30 1.07 .97 .97
KLA/ATP .93 1.00 1.07 1.20 1.02 .96 .94
Baiap2
KLA  ATP  ATP+KLA
 NM_001037754 brain-specific angiogenesis inhibitor 1-associated protein 2 (Baiap2), transcript variant 3, mRNA [NM_001037754] KLA .70 .70 .71 .66 .63 .78 .60
ATP 1.03 1.19 1.30 3.72 4.02 2.43 2.11
KLA/ATP .71 .76 .84 2.81 4.32 4.09 2.11
Baiap2
KLA  ATP  ATP+KLA
 NM_130862 brain-specific angiogenesis inhibitor 1-associated protein 2 (Baiap2), transcript variant 2, mRNA [NM_130862] KLA .59 .59 .55 .56 .47 .55 .56
ATP .88 .92 1.04 1.12 .62 .98 2.48
KLA/ATP .57 .56 .63 .72 .63 1.00 1.41
Bcar1
KLA  ATP  ATP+KLA
 NM_009954 breast cancer anti-estrogen resistance 1 (Bcar1), mRNA [NM_009954] KLA .88 .87 .82 .88 1.06 1.12 1.70
ATP 1.04 1.05 1.00 1.27 1.34 1.62 1.34
KLA/ATP .95 .87 .87 .95 1.02 1.17 2.10
Bdkrb1
KLA  ATP  ATP+KLA
 NM_007539 bradykinin receptor, beta 1 (Bdkrb1), mRNA [NM_007539] KLA 1.60 1.44 1.47 1.36 1.29 1.38 1.04
ATP 1.05 .99 1.17 1.12 1.15 1.16 .95
KLA/ATP 1.51 1.59 1.94 1.30 1.22 1.23 1.20
Bdkrb2
KLA  ATP  ATP+KLA
 NM_009747 bradykinin receptor, beta 2 (Bdkrb2), mRNA [NM_009747] KLA .97 .96 1.01 1.09 1.01 1.00 1.08
ATP 1.07 .98 1.04 1.01 1.05 1.00 1.08
KLA/ATP 1.02 1.05 1.04 1.01 1.03 1.04 .98
Braf
KLA  ATP  ATP+KLA
 NM_139294 Braf transforming gene (Braf), mRNA [NM_139294] KLA 1.52 1.57 1.55 1.33 1.83 1.52 1.60
ATP 1.08 1.17 1.02 1.37 .95 1.15 .95
KLA/ATP 1.64 1.69 1.39 1.51 1.04 1.31 1.26
Cd14
KLA  ATP  ATP+KLA
 NM_009841 CD14 antigen (Cd14), mRNA [NM_009841] KLA 2.35 2.68 2.54 2.21 2.39 1.52 1.57
ATP 1.44 2.28 2.82 3.98 6.68 16.14 6.92
KLA/ATP 2.92 3.79 3.96 5.12 5.29 10.42 11.50
Cdc42
KLA  ATP  ATP+KLA
 NM_009861 cell division cycle 42 homolog (S. cerevisiae) (Cdc42), mRNA [NM_009861] KLA 1.04 1.01 1.02 1.04 1.12 1.21 1.12
ATP 1.07 1.10 1.04 1.06 1.02 .95 1.14
KLA/ATP .94 1.04 1.01 .97 .95 1.02 1.25
Cfl1
KLA  ATP  ATP+KLA
 NM_007687 cofilin 1, non-muscle (Cfl1), mRNA [NM_007687] KLA .90 1.01 1.14 .87 1.17 1.17 1.48
ATP 1.24 1.60 .81 1.77 1.07 .88 1.27
KLA/ATP 1.33 1.48 .50 1.58 .71 .93 1.31
Cfl2
KLA  ATP  ATP+KLA
 NM_007688 cofilin 2, muscle (Cfl2), mRNA [NM_007688] KLA .62 .65 .74 .97 .99 .97 1.03
ATP .57 .49 .50 .49 .94 .97 .76
KLA/ATP .47 .41 .44 .58 1.02 1.05 .93
Chrm1
KLA  ATP  ATP+KLA
 NM_001112697 cholinergic receptor, muscarinic 1, CNS (Chrm1), transcript variant 1, mRNA [NM_001112697] KLA 1.12 .99 .97 1.09 .92 .91 .97
ATP .95 1.06 1.01 1.06 1.05 1.06 .99
KLA/ATP 1.00 .99 1.02 1.00 1.05 .95 1.01
Chrm2
KLA  ATP  ATP+KLA
 NM_203491 cholinergic receptor, muscarinic 2, cardiac (Chrm2), mRNA [NM_203491] KLA 1.03 1.05 .98 1.02 1.04 1.06 1.05
ATP 1.09 .94 1.08 1.06 .98 1.04 .97
KLA/ATP 1.01 1.05 .97 1.01 .98 1.07 .99
Chrm3
KLA  ATP  ATP+KLA
 AK051841 12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230008K23 product:unclassifiable, full insert sequence. [AK051841] KLA .92 .97 1.02 1.05 .96 .99 1.00
ATP 1.00 .99 .99 .95 1.05 1.02 1.01
KLA/ATP .91 .98 1.06 1.07 .94 1.00 .94
Chrm3
KLA  ATP  ATP+KLA
 NM_033269 cholinergic receptor, muscarinic 3, cardiac (Chrm3), mRNA [NM_033269] KLA .91 .99 .98 .93 1.08 1.01 1.06
ATP .97 1.05 1.03 .95 .99 1.01 1.10
KLA/ATP 1.05 1.09 .99 1.00 .98 1.03 1.00
Chrm4
KLA  ATP  ATP+KLA
 NM_007699 cholinergic receptor, muscarinic 4 (Chrm4), mRNA [NM_007699] KLA .95 1.01 .97 .97 .96 1.07 1.04
ATP 1.08 1.01 1.04 1.08 1.01 .99 .98
KLA/ATP 1.01 1.04 1.04 .99 .99 .96 .99
Chrm5
KLA  ATP  ATP+KLA
 NM_205783 cholinergic receptor, muscarinic 5 (Chrm5), mRNA [NM_205783] KLA .98 1.02 .96 .98 1.03 1.02 1.02
ATP 1.02 .96 .96 1.15 1.00 1.06 1.04
KLA/ATP 1.02 .90 .95 1.05 1.04 1.05 .95
Crk
KLA  ATP  ATP+KLA
 NM_133656 v-crk sarcoma virus CT10 oncogene homolog (avian) (Crk), mRNA [NM_133656] KLA 1.29 1.32 1.41 1.38 1.75 1.59 1.52
ATP 1.08 1.17 1.01 .93 1.27 2.11 1.70
KLA/ATP 1.37 1.49 1.14 1.09 1.21 1.69 2.32
Crkl
KLA  ATP  ATP+KLA
 NM_007764 v-crk sarcoma virus CT10 oncogene homolog (avian)-like (Crkl), mRNA [NM_007764] KLA 1.85 1.97 2.08 1.73 1.66 1.64 1.36
ATP .97 .94 .78 .74 1.46 1.89 1.46
KLA/ATP 1.92 1.88 1.18 1.44 1.67 2.65 2.72
Cyfip1
KLA  ATP  ATP+KLA
 AF072697 SHYC (Shyc) mRNA, complete cds. [AF072697] KLA 1.49 1.21 1.31 2.03 2.22 2.97 2.66
ATP .99 .96 1.08 .89 .74 .90 1.45
KLA/ATP 1.15 1.15 1.65 1.20 .88 .87 3.00
Cyfip1
KLA  ATP  ATP+KLA
 NM_011370 cytoplasmic FMR1 interacting protein 1 (Cyfip1), mRNA [NM_011370] KLA 1.32 1.33 1.49 1.53 1.97 2.66 2.95
ATP 1.00 1.03 .94 .87 .70 .77 1.55
KLA/ATP 1.30 1.35 1.24 1.10 .76 .83 2.61
Cyfip2
KLA  ATP  ATP+KLA
 BC056974 cytoplasmic FMR1 interacting protein 2, mRNA (cDNA clone MGC:66804 IMAGE:6831770), complete cds. [BC056974] KLA 1.07 1.09 1.18 1.18 1.23 1.17 1.61
ATP 1.14 1.46 1.73 1.96 2.02 1.65 1.43
KLA/ATP 1.14 1.26 1.30 1.45 1.30 1.38 2.16
Cyfip2
KLA  ATP  ATP+KLA
 NM_133769 cytoplasmic FMR1 interacting protein 2 (Cyfip2), mRNA [NM_133769] KLA .93 .94 .94 .82 .93 1.16 2.12
ATP 1.18 1.27 .99 1.33 1.46 1.03 1.06
KLA/ATP 1.03 .98 .73 1.09 1.27 1.41 1.68
Diap1
KLA  ATP  ATP+KLA
 BC070412 diaphanous homolog 1 (Drosophila), mRNA (cDNA clone MGC:86169 IMAGE:5705112), complete cds [BC070412] KLA .91 .97 .93 .75 .83 .85 1.02
ATP 1.08 1.18 1.07 1.07 1.12 1.11 1.15
KLA/ATP 1.01 1.00 .74 .83 .83 .94 1.09
Diap1
KLA  ATP  ATP+KLA
 NM_007858 diaphanous homolog 1 (Drosophila) (Diap1), mRNA [NM_007858] KLA 1.10 1.23 1.25 1.04 1.11 1.00 1.17
ATP 1.20 1.38 1.02 1.43 1.43 1.27 1.28
KLA/ATP 1.43 1.38 .88 1.30 1.04 1.18 1.56
Diap2
KLA  ATP  ATP+KLA
 AK040942 adult male aorta and vein cDNA, RIKEN full-length enriched library, clone:A530048N20 product:unclassifiable, full insert sequence. [AK040942] KLA 1.49 1.39 1.41 1.37 1.32 1.15 1.14
ATP 1.06 1.10 1.43 1.04 1.02 1.11 1.04
KLA/ATP 1.42 1.51 1.46 1.46 1.22 1.05 1.02
Diap2
KLA  ATP  ATP+KLA
 NM_017398 diaphanous homolog 2 (Drosophila) (Diap2), mRNA [NM_017398] KLA 2.17 2.41 2.55 2.68 3.15 2.46 2.28
ATP 1.04 1.17 1.01 1.16 .95 .91 .92
KLA/ATP 2.51 2.64 2.11 2.42 1.46 .91 1.23
Diap3
KLA  ATP  ATP+KLA
 NM_019670 diaphanous homolog 3 (Drosophila) (Diap3), mRNA [NM_019670] KLA 1.11 1.10 .99 .90 .75 .50 .33
ATP 1.00 1.01 1.19 1.22 .93 .88 .33
KLA/ATP 1.09 1.10 1.11 1.11 .78 .57 .33
Dock1
KLA  ATP  ATP+KLA
 AK163853 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130086K10 product:dedicator of cyto-kinesis 1, full insert sequence. [AK163853] KLA .94 .92 .94 .89 .75 .72 .75
ATP 1.04 1.01 .93 .84 .69 .63 1.16
KLA/ATP .84 .87 .76 .78 .71 .66 .65
Dock1
KLA  ATP  ATP+KLA
 NM_001033420 dedicator of cytokinesis 1 (Dock1), mRNA [NM_001033420] KLA 1.15 .95 .89 .75 .42 .19 .31
ATP 1.01 .83 .45 .41 .30 .17 .37
KLA/ATP .94 .85 .40 .24 .16 .15 .16
Egf
KLA  ATP  ATP+KLA
 NM_010113 epidermal growth factor (Egf), mRNA [NM_010113] KLA .89 .90 .81 .83 .83 .86 .92
ATP 1.03 1.03 .95 .84 .67 .79 .88
KLA/ATP .86 .86 .77 .77 .69 .78 .83
Egfr
KLA  ATP  ATP+KLA
 NM_007912 epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] KLA 1.10 1.07 1.14 1.11 1.08 1.03 .90
ATP .99 1.00 1.04 .98 .97 1.15 1.14
KLA/ATP 1.07 1.10 1.16 1.08 1.01 .97 .94
Egfr
KLA  ATP  ATP+KLA
 NM_207655 epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] KLA 1.57 1.44 1.47 1.31 .96 .92 .76
ATP .97 .93 1.10 1.00 1.41 2.97 .86
KLA/ATP 1.44 1.50 1.61 1.30 1.14 1.21 .82
Enah
KLA  ATP  ATP+KLA
 AK020248 adult male colon cDNA, RIKEN full-length enriched library, clone:9030215D04 product:enabled homolog (Drosophila), full insert sequence. [AK020248] KLA .96 .97 .99 1.00 1.07 1.06 1.03
ATP 1.00 .99 .96 1.07 1.04 1.03 1.01
KLA/ATP .97 .99 .90 1.00 1.05 1.07 1.04
Enah
KLA  ATP  ATP+KLA
 AK076131 10, 11 days embryo whole body cDNA, RIKEN full-length enriched library, clone:2810468A07 product:unclassifiable, full insert sequence [AK076131] KLA 1.03 1.01 1.17 1.10 1.11 1.10 1.03
ATP 1.06 .95 1.14 1.14 1.10 1.13 1.04
KLA/ATP 1.08 1.03 1.20 1.21 1.14 1.43 1.10
Enah
KLA  ATP  ATP+KLA
 NM_010135 enabled homolog (Drosophila) (Enah), transcript variant 1, mRNA [NM_010135] KLA 1.04 1.06 1.12 1.20 1.14 1.14 1.11
ATP 1.02 .98 1.12 1.41 1.25 1.54 1.21
KLA/ATP 1.06 1.09 1.24 1.52 1.42 1.73 1.67
Ezr
KLA  ATP  ATP+KLA
 NM_009510 ezrin (Ezr), mRNA [NM_009510] KLA 2.87 2.71 2.24 2.32 2.31 1.91 1.08
ATP 1.04 1.05 1.11 1.87 4.65 5.96 1.64
KLA/ATP 2.94 2.63 2.59 3.03 2.98 3.38 4.32
F2
KLA  ATP  ATP+KLA
 NM_010168 coagulation factor II (F2), mRNA [NM_010168] KLA .99 .92 .95 1.01 1.01 1.06 .97
ATP 1.03 1.02 1.04 1.07 1.08 .96 .99
KLA/ATP .95 1.04 1.02 1.02 1.04 1.07 .99
F2r
KLA  ATP  ATP+KLA
 NM_010169 coagulation factor II (thrombin) receptor (F2r), mRNA [NM_010169] KLA 3.73 3.81 3.68 3.00 2.75 1.49 1.01
ATP .98 1.02 1.25 1.24 1.31 1.63 1.16
KLA/ATP 3.51 4.05 3.49 3.00 2.48 1.69 1.23
Fgd1
KLA  ATP  ATP+KLA
 NM_008001 FYVE, RhoGEF and PH domain containing 1 (Fgd1), mRNA [NM_008001] KLA 1.04 1.02 1.03 1.04 .95 .92 .84
ATP 1.00 1.02 .90 .94 .89 .92 .85
KLA/ATP 1.07 1.05 1.04 .97 .90 .96 .84
Fgd3
KLA  ATP  ATP+KLA
 NM_015759 FYVE, RhoGEF and PH domain containing 3 (Fgd3), mRNA [NM_015759] KLA .36 .33 .36 .49 .88 .90 1.01
ATP .97 .88 .84 .85 .66 1.50 1.93
KLA/ATP .37 .34 .40 .42 .57 .79 1.88
Fgf1
KLA  ATP  ATP+KLA
 NM_010197 fibroblast growth factor 1 (Fgf1), mRNA [NM_010197] KLA 1.07 .99 .99 1.00 1.03 .97 .99
ATP 1.01 1.03 1.01 .95 .95 .98 .88
KLA/ATP 1.03 .99 .97 .99 .98 .94 1.01
Fgf10
KLA  ATP  ATP+KLA
 NM_008002 fibroblast growth factor 10 (Fgf10), mRNA [NM_008002] KLA .99 .98 1.02 1.00 1.02 1.02 1.02
ATP 1.03 1.02 1.00 1.00 1.00 .99 .99
KLA/ATP 1.01 1.00 1.04 .99 1.00 1.02 1.01
Fgf11
KLA  ATP  ATP+KLA
 BC066859 fibroblast growth factor 11, mRNA (cDNA clone MGC:76712 IMAGE:30101881), complete cds [BC066859] KLA .64 .61 .55 .58 .51 .48 .77
ATP 1.00 .96 .78 .78 .63 .44 .48
KLA/ATP .64 .63 .59 .56 .54 .42 .40
Fgf11
KLA  ATP  ATP+KLA
 NM_010198 fibroblast growth factor 11 (Fgf11), mRNA [NM_010198] KLA .99 1.02 1.05 1.04 1.01 1.03 1.07
ATP .95 1.02 1.02 1.07 .98 1.01 1.07
KLA/ATP 1.01 1.01 1.08 .96 .97 .95 1.01
Fgf12
KLA  ATP  ATP+KLA
 NM_183064 fibroblast growth factor 12 (Fgf12), transcript variant 1, mRNA [NM_183064] KLA .96 .97 1.05 .99 .97 1.01 1.01
ATP .93 .97 .97 .97 .99 .95 1.00
KLA/ATP 1.02 1.05 1.10 1.02 .95 1.01 .95
Fgf13
KLA  ATP  ATP+KLA
 NM_010200 fibroblast growth factor 13 (Fgf13), mRNA [NM_010200] KLA .91 .92 .93 .84 .77 .66 .75
ATP 1.09 1.14 1.03 1.11 1.06 .68 .78
KLA/ATP .98 1.02 .86 .90 .78 .70 .79
Fgf14
KLA  ATP  ATP+KLA
 NM_010201 fibroblast growth factor 14 (Fgf14), transcript variant 1, mRNA [NM_010201] KLA 1.04 1.05 1.02 1.04 1.03 1.05 1.03
ATP .99 1.08 1.04 1.00 .99 .98 1.04
KLA/ATP 1.00 1.00 1.08 1.00 1.04 1.01 1.03
Fgf14
KLA  ATP  ATP+KLA
 NM_207667 fibroblast growth factor 14 (Fgf14), transcript variant 2, mRNA [NM_207667] KLA 1.04 1.01 .98 .93 .96 .96 .97
ATP 1.04 1.10 .94 .87 1.03 .99 .96
KLA/ATP .86 .94 1.03 .89 1.00 .90 1.03
Fgf15
KLA  ATP  ATP+KLA
 NM_008003 fibroblast growth factor 15 (Fgf15), mRNA [NM_008003] KLA 1.00 1.00 .95 .98 .92 .96 1.01
ATP .99 1.01 .98 .98 .93 .95 .97
KLA/ATP .98 1.01 1.02 1.03 .97 .97 1.00
Fgf16
KLA  ATP  ATP+KLA
 NM_030614 fibroblast growth factor 16 (Fgf16), mRNA [NM_030614] KLA 1.00 .97 .99 1.02 1.04 .97 .97
ATP 1.02 .99 .99 1.02 1.12 1.01 1.02
KLA/ATP 1.06 1.02 .99 1.01 1.00 1.10 1.03
Fgf17
KLA  ATP  ATP+KLA
 NM_008004 fibroblast growth factor 17 (Fgf17), mRNA [NM_008004] KLA .97 1.03 .98 1.00 .97 .97 .86
ATP .99 .96 .99 .90 1.02 1.01 1.01
KLA/ATP .99 .91 1.08 .99 .99 .98 .99
Fgf18
KLA  ATP  ATP+KLA
 NM_008005 fibroblast growth factor 18 (Fgf18), mRNA [NM_008005] KLA 1.17 1.18 1.16 1.12 1.03 1.13 1.04
ATP .96 .98 2.47 12.57 2.76 1.56 1.03
KLA/ATP 1.01 1.15 2.33 10.13 2.80 1.79 1.02
Fgf2
KLA  ATP  ATP+KLA
 NM_008006 fibroblast growth factor 2 (Fgf2), mRNA [NM_008006] KLA 1.02 1.01 1.00 1.03 1.01 1.02 1.01
ATP .99 1.01 1.00 1.02 1.01 1.01 1.00
KLA/ATP 1.00 1.01 .98 1.01 1.02 1.03 1.01
Fgf20
KLA  ATP  ATP+KLA
 NM_030610 fibroblast growth factor 20 (Fgf20), mRNA [NM_030610] KLA .97 1.08 .99 1.00 .97 1.00 .97
ATP 1.03 .95 .97 1.05 .98 .97 1.00
KLA/ATP .99 .99 1.06 1.04 1.02 .92 .96
Fgf21
KLA  ATP  ATP+KLA
 NM_020013 fibroblast growth factor 21 (Fgf21), mRNA [NM_020013] KLA 1.02 1.03 .87 1.04 1.00 1.01 1.00
ATP 1.04 .97 1.00 1.02 .96 1.05 1.02
KLA/ATP 1.08 1.00 1.00 1.00 1.03 1.02 .99
Fgf22
KLA  ATP  ATP+KLA
 AK008922 adult male stomach cDNA, RIKEN full-length enriched library, clone:2210414E06 product:FIBROBLAST GROWTH FACTOR-22 PRECURSOR (FGF-22) homolog [Mus musculus], full insert sequence [AK008922] KLA .90 .94 .95 1.04 1.03 .94 .97
ATP 1.04 1.01 .98 .93 .93 .95 .88
KLA/ATP .98 .97 .97 1.01 .95 .92 .95
Fgf22
KLA  ATP  ATP+KLA
 NM_023304 fibroblast growth factor 22 (Fgf22), mRNA [NM_023304] KLA .99 .94 1.01 .95 .97 .89 .99
ATP 1.00 .95 1.00 .96 .97 .93 .98
KLA/ATP .91 1.00 1.01 .92 .95 .98 .97
Fgf23
KLA  ATP  ATP+KLA
 NM_022657 fibroblast growth factor 23 (Fgf23), mRNA [NM_022657] KLA 1.32 1.39 1.27 1.22 1.07 1.03 1.14
ATP .95 1.00 1.05 1.07 1.05 1.02 .96
KLA/ATP 1.32 1.39 1.37 1.22 1.01 1.00 .90
Fgf3
KLA  ATP  ATP+KLA
 NM_008007 fibroblast growth factor 3 (Fgf3), mRNA [NM_008007] KLA 1.03 1.05 1.00 .97 1.01 .98 .97
ATP 1.01 1.00 .97 1.03 .98 1.03 .97
KLA/ATP .98 1.00 1.01 1.03 1.03 1.00 .99
Fgf5
KLA  ATP  ATP+KLA
 NM_010203 fibroblast growth factor 5 (Fgf5), mRNA [NM_010203] KLA 1.02 1.02 1.00 1.03 .97 1.05 .99
ATP 1.02 1.00 1.03 .97 .99 .97 1.04
KLA/ATP 1.05 .92 1.01 1.00 1.11 .96 .97
Fgf6
KLA  ATP  ATP+KLA
 M92416 fibroblast growth factor (Fgf6) mRNA, 3 end [M92416] KLA 1.09 1.07 1.00 1.06 .97 1.01 .96
ATP 1.02 1.02 1.06 1.02 .93 .99 .98
KLA/ATP 1.04 .99 1.00 .99 1.00 1.00 1.03
Fgf6
KLA  ATP  ATP+KLA
 NM_010204 fibroblast growth factor 6 (Fgf6), mRNA [NM_010204] KLA 1.00 .96 1.06 .96 .96 1.00 .91
ATP .94 1.00 .89 .95 1.01 .92 1.00
KLA/ATP .99 1.06 1.06 .86 1.00 .95 1.00
Fgf7
KLA  ATP  ATP+KLA
 NM_008008 fibroblast growth factor 7 (Fgf7), mRNA [NM_008008] KLA 1.02 1.02 1.02 1.03 1.05 1.11 1.04
ATP 1.00 1.01 1.11 1.15 1.05 1.04 1.06
KLA/ATP .99 .96 .83 1.10 1.15 1.26 1.21
Fgf8
KLA  ATP  ATP+KLA
 BC048734 fibroblast growth factor 8, mRNA (cDNA clone MGC:59627 IMAGE:6513131), complete cds [BC048734] KLA .96 .95 1.03 .96 1.06 .97 .96
ATP 1.08 .94 1.07 1.10 1.00 .93 1.06
KLA/ATP 1.03 1.02 1.04 .96 1.04 .94 .94
Fgf8
KLA  ATP  ATP+KLA
 NM_010205 fibroblast growth factor 8 (Fgf8), mRNA [NM_010205] KLA 1.00 1.00 1.03 1.04 1.04 1.07 1.09
ATP 1.01 1.01 1.11 1.14 1.11 1.09 1.05
KLA/ATP 1.00 1.04 1.14 1.18 1.15 1.09 1.04
Fgf9
KLA  ATP  ATP+KLA
 NM_013518 fibroblast growth factor 9 (Fgf9), mRNA [NM_013518] KLA 1.04 1.07 1.07 1.12 .97 .96 .91
ATP 1.02 1.08 .98 1.00 .94 .99 .92
KLA/ATP 1.04 1.03 1.03 1.00 .93 .93 .89
Fgfr1
KLA  ATP  ATP+KLA
 M28998 gb|Mouse basic fibroblast growth factor receptor (bFGF-R) mRNA, complete cds. [M28998] KLA .82 .79 .73 .66 .50 .55 .65
ATP 1.01 1.08 .86 .90 1.29 1.24 1.52
KLA/ATP .85 .82 .71 .71 .63 .80 .85
Fgfr1
KLA  ATP  ATP+KLA
 NM_010206 fibroblast growth factor receptor 1 (Fgfr1), transcript variant 1, mRNA [NM_010206] KLA .92 .86 .73 .82 .79 .85 .84
ATP 1.01 1.06 .92 .92 1.18 1.02 1.22
KLA/ATP .83 .83 .79 .76 .83 .83 .92
Fgfr2
KLA  ATP  ATP+KLA
 NM_010207 fibroblast growth factor receptor 2 (Fgfr2), transcript variant 1, mRNA [NM_010207] KLA 1.01 .98 1.00 1.01 .98 1.00 .99
ATP 1.00 1.03 1.05 1.03 1.01 1.01 1.00
KLA/ATP 1.00 1.01 1.04 1.01 .99 1.02 1.03
Fgfr3
KLA  ATP  ATP+KLA
 NM_008010 fibroblast growth factor receptor 3 (Fgfr3), mRNA [NM_008010] KLA 1.09 1.15 1.05 1.10 1.02 1.05 1.12
ATP 1.05 .94 .98 .87 .91 .95 .92
KLA/ATP 1.13 1.11 1.10 .91 .92 .93 .92
Fgfr4
KLA  ATP  ATP+KLA
 AF127140 fibroblast growth factor receptor 4 splice variant 17b (Fgfr4) mRNA, partial cds. [AF127140] KLA .96 .97 1.06 .97 1.05 1.05 1.08
ATP 1.02 .98 1.07 1.23 1.15 1.18 1.31
KLA/ATP .91 1.02 1.08 1.16 1.07 1.05 1.23
Fgfr4
KLA  ATP  ATP+KLA
 NM_008011 fibroblast growth factor receptor 4 (Fgfr4), mRNA [NM_008011] KLA 1.08 1.11 1.09 1.06 .99 1.06 1.03
ATP 1.05 .96 1.17 1.06 1.10 1.04 1.01
KLA/ATP 1.03 .98 1.10 1.06 1.05 1.06 1.04
Fn1
KLA  ATP  ATP+KLA
 NM_010233 fibronectin 1 (Fn1), mRNA [NM_010233] KLA 1.23 1.30 1.38 1.12 1.16 1.00 .78
ATP 1.02 1.19 1.25 1.56 1.33 1.05 .95
KLA/ATP 1.36 1.51 1.34 1.70 1.20 1.06 .93
Git1
KLA  ATP  ATP+KLA
 NM_001004144 G protein-coupled receptor kinase-interactor 1 (Git1), mRNA [NM_001004144] KLA .95 1.03 1.19 .93 1.13 1.05 1.26
ATP 1.14 1.52 .93 1.50 1.64 1.24 1.68
KLA/ATP 1.29 1.28 .74 1.31 1.07 1.32 1.88
Gna12
KLA  ATP  ATP+KLA
 M63659 gb|Mouse G-alpha-12 protein mRNA, complete cds [M63659] KLA .48 .48 .49 .40 .44 .59 .60
ATP 1.08 1.15 1.00 1.39 1.02 .65 .73
KLA/ATP .52 .50 .51 .52 .56 .66 .52
Gna13
KLA  ATP  ATP+KLA
 NM_010303 guanine nucleotide binding protein, alpha 13 (Gna13), mRNA [NM_010303] KLA 1.96 2.10 2.12 1.85 2.36 2.02 1.54
ATP 1.04 1.13 1.19 3.56 6.50 2.32 1.44
KLA/ATP 2.17 2.07 1.67 3.72 6.89 3.91 2.27
Gng12
KLA  ATP  ATP+KLA
 NM_025278 guanine nucleotide binding protein (G protein), gamma 12 (Gng12), mRNA [NM_025278] KLA 2.21 2.23 2.48 2.62 2.47 2.28 1.68
ATP 1.02 1.02 1.09 1.10 1.20 1.32 1.01
KLA/ATP 2.10 2.17 2.38 2.40 1.91 1.60 1.77
Grlf1
KLA  ATP  ATP+KLA
 NM_172739 glucocorticoid receptor DNA binding factor 1 (Grlf1), mRNA [NM_172739] KLA 1.65 1.31 1.14 1.07 .99 1.16 .94
ATP .85 .69 .90 .69 .86 1.87 .87
KLA/ATP 1.26 1.23 1.21 .76 1.23 1.99 1.66
Gsn
KLA  ATP  ATP+KLA
 NM_146120 gelsolin (Gsn), mRNA [NM_146120] KLA .71 .69 .70 .61 .47 .39 .32
ATP .99 .86 .95 .65 .61 .44 .46
KLA/ATP .71 .80 .61 .48 .43 .32 .20
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Ins1
KLA  ATP  ATP+KLA
 NM_008386 insulin I (Ins1), mRNA [NM_008386] KLA 1.00 .99 .99 1.03 1.01 .98 1.06
ATP .97 1.03 1.00 1.03 .99 1.07 1.05
KLA/ATP 1.03 .93 .98 1.04 1.07 1.03 1.01
Ins2
KLA  ATP  ATP+KLA
 NM_008387 insulin II (Ins2), mRNA [NM_008387] KLA .99 1.00 1.00 1.01 1.00 1.02 1.00
ATP 1.01 .99 1.00 1.00 .98 .99 1.01
KLA/ATP .99 1.01 1.00 .98 .99 .99 .98
Insrr
KLA  ATP  ATP+KLA
 NM_011832 insulin receptor-related receptor (Insrr), mRNA [NM_011832] KLA 1.11 1.18 1.18 1.17 1.16 1.19 1.16
ATP .93 .91 1.08 1.07 1.21 1.11 .99
KLA/ATP 1.09 1.14 1.16 1.13 1.15 1.19 1.03
Iqgap1
KLA  ATP  ATP+KLA
 NM_016721 IQ motif containing GTPase activating protein 1 (Iqgap1), mRNA [NM_016721] KLA 1.02 1.12 1.02 .85 .93 .86 .84
ATP 1.08 1.17 .93 1.22 .89 .68 1.00
KLA/ATP 1.17 1.13 .76 1.00 .67 .69 1.08
Iqgap2
KLA  ATP  ATP+KLA
 NM_027711 IQ motif containing GTPase activating protein 2 (Iqgap2), mRNA [NM_027711] KLA .95 1.03 1.09 .99 .99 .88 .98
ATP 1.11 1.24 1.04 1.15 .68 .77 .33
KLA/ATP .98 1.08 .88 1.07 .63 .81 .40
Iqgap3
KLA  ATP  ATP+KLA
 AK050913 9 days embryo whole body cDNA, RIKEN full-length enriched library, clone:D030034H08 product:hypothetical protein, full insert sequence. [AK050913] KLA .97 .98 .95 .99 1.01 .93 .94
ATP .99 1.00 1.01 .97 .99 .97 .92
KLA/ATP .96 .98 .98 .95 .95 .91 .93
Iqgap3
KLA  ATP  ATP+KLA
 NM_001033484 IQ motif containing GTPase activating protein 3 (Iqgap3), mRNA [NM_001033484] KLA .79 .77 .78 .61 .42 .23 .15
ATP 1.11 1.30 1.04 1.64 .81 .30 .16
KLA/ATP .96 .82 .65 .89 .51 .23 .15
Itga1
KLA  ATP  ATP+KLA
 NM_001033228 integrin alpha 1 (Itga1), mRNA [NM_001033228] KLA 1.08 1.09 1.13 1.05 1.04 .99 1.01
ATP 1.02 .97 1.03 1.03 1.09 1.43 3.50
KLA/ATP 1.06 1.04 1.07 1.00 1.06 1.12 1.33
Itga10
KLA  ATP  ATP+KLA
 NM_001081053 integrin, alpha 10 (Itga10), mRNA [NM_001081053] KLA .98 1.00 1.00 1.04 1.04 .96 1.00
ATP 1.05 1.00 .97 .98 .95 .96 .97
KLA/ATP 1.04 .98 .92 .96 .95 .97 1.00
Itga11
KLA  ATP  ATP+KLA
 NM_176922 integrin, alpha 11 (Itga11), mRNA [NM_176922] KLA .95 .92 .90 .97 .93 .93 .96
ATP .97 .92 .98 .95 .90 .94 .95
KLA/ATP .86 .94 1.01 .93 .97 .94 .88
Itga2
KLA  ATP  ATP+KLA
 NM_008396 integrin alpha 2 (Itga2), mRNA [NM_008396] KLA 1.03 1.00 .98 1.01 .97 .96 1.00
ATP 1.05 .99 .93 1.02 1.04 1.03 .97
KLA/ATP .98 1.06 1.03 1.00 1.00 1.01 1.01
Itga2b
KLA  ATP  ATP+KLA
 NM_010575 integrin alpha 2b (Itga2b), mRNA [NM_010575] KLA 1.01 1.00 .98 1.04 1.01 1.04 1.18
ATP 1.01 .98 .95 1.02 .96 1.13 1.08
KLA/ATP 1.04 1.02 1.02 .95 1.05 1.53 1.23
Itga3
KLA  ATP  ATP+KLA
 NM_013565 integrin alpha 3 (Itga3), mRNA [NM_013565] KLA 1.06 1.09 1.10 1.17 1.19 1.29 1.41
ATP .99 .99 1.05 1.12 1.20 1.25 1.33
KLA/ATP 1.08 1.14 1.15 1.27 1.28 1.20 1.39
Itga4
KLA  ATP  ATP+KLA
 NM_010576 integrin alpha 4 (Itga4), mRNA [NM_010576] KLA 4.65 4.83 4.47 3.76 2.93 1.65 1.01
ATP 1.10 1.12 1.17 1.08 .86 .75 .36
KLA/ATP 4.82 5.02 4.43 3.69 2.11 1.13 .79
Itga5
KLA  ATP  ATP+KLA
 NM_010577 integrin alpha 5 (fibronectin receptor alpha) (Itga5), mRNA [NM_010577] KLA 2.63 3.04 2.81 2.47 4.61 5.45 4.90
ATP 1.13 1.62 .74 2.21 1.31 1.93 2.84
KLA/ATP 3.55 3.84 1.15 3.03 1.11 2.81 10.42
Itga6
KLA  ATP  ATP+KLA
 BC024571 integrin alpha 6, mRNA (cDNA clone IMAGE:5036677). [BC024571] KLA .44 .44 .37 .28 .25 .29 .34
ATP .96 1.01 .90 .58 .35 .11 .22
KLA/ATP .44 .41 .34 .23 .15 .09 .08
Itga6
KLA  ATP  ATP+KLA
 NM_008397 integrin alpha 6 (Itga6), mRNA [NM_008397] KLA .57 .58 .51 .45 .43 .44 .47
ATP 1.05 1.12 .86 .90 .57 .27 .36
KLA/ATP .64 .67 .50 .57 .39 .29 .26
Itga7
KLA  ATP  ATP+KLA
 L23423 gb|Mouse (BALB/c) alpha-7 integrin mRNA, complete cds. [L23423] KLA .96 1.03 1.00 1.07 1.02 1.07 1.14
ATP 1.00 1.00 1.04 1.88 2.09 1.34 1.16
KLA/ATP 1.04 .97 1.07 1.79 1.68 1.39 1.11
Itga7
KLA  ATP  ATP+KLA
 NM_008398 integrin alpha 7 (Itga7), mRNA [NM_008398] KLA .98 .95 .98 1.01 1.04 1.03 .98
ATP 1.00 1.02 1.06 1.75 1.92 1.20 1.02
KLA/ATP 1.03 1.07 1.06 1.48 1.58 1.23 1.05
Itga8
KLA  ATP  ATP+KLA
 NM_001001309 integrin alpha 8 (Itga8), mRNA [NM_001001309] KLA .80 .81 .79 .75 .63 .61 .44
ATP .98 1.04 1.06 .94 .79 .61 .50
KLA/ATP .79 .81 .81 .71 .70 .65 .48
Itgae
KLA  ATP  ATP+KLA
 NM_008399 integrin, alpha E, epithelial-associated (Itgae), transcript variant 1, mRNA [NM_008399] KLA 1.05 1.12 1.30 1.29 1.36 1.38 1.17
ATP .97 1.03 1.02 1.03 1.03 1.06 1.05
KLA/ATP 1.11 1.15 1.23 1.19 1.29 2.36 1.81
Itgae
KLA  ATP  ATP+KLA
 NM_172944 integrin, alpha E, epithelial-associated (Itgae), transcript variant 2, mRNA [NM_172944] KLA 1.08 1.13 1.12 1.25 1.11 1.15 1.05
ATP .97 .99 .99 1.01 1.04 .99 1.13
KLA/ATP 1.09 .99 1.10 1.04 1.07 1.42 1.33
Itgal
KLA  ATP  ATP+KLA
 AK156251 activated spleen cDNA, RIKEN full-length enriched library, clone:F830013L17 product:integrin alpha L, full insert sequence [AK156251] KLA 5.36 5.78 4.86 5.55 7.02 8.63 11.12
ATP .99 1.17 1.22 1.57 1.35 1.95 3.79
KLA/ATP 5.42 5.89 4.95 5.91 3.96 4.93 10.15
Itgal
KLA  ATP  ATP+KLA
 NM_008400 integrin alpha L (Itgal), mRNA [NM_008400] KLA 4.48 5.17 5.28 5.82 7.82 8.09 16.96
ATP 1.03 1.06 1.24 1.44 1.34 2.02 4.59
KLA/ATP 4.71 5.63 5.49 5.60 3.66 4.65 17.76
Itgam
KLA  ATP  ATP+KLA
 NM_001082960 integrin alpha M (Itgam), transcript variant 1, mRNA [NM_001082960] KLA 1.04 1.12 1.14 1.07 1.54 1.80 1.72
ATP 1.17 1.19 .97 1.16 .86 .65 1.33
KLA/ATP 1.19 1.19 .94 1.06 .64 .59 1.08
Itgam
KLA  ATP  ATP+KLA
 NM_008401 integrin alpha M (Itgam), transcript variant 2, mRNA [NM_008401] KLA 1.20 1.16 1.21 1.34 1.59 1.79 1.64
ATP 1.15 1.16 .94 1.20 1.00 .78 1.25
KLA/ATP 1.32 1.37 1.29 1.14 .84 .75 1.16
Itgav
KLA  ATP  ATP+KLA
 AK052514 13 days embryo lung cDNA, RIKEN full-length enriched library, clone:D430040G12 product:hypothetical protein, full insert sequence. [AK052514] KLA 1.04 .93 1.05 1.02 1.01 .93 1.03
ATP 1.05 1.04 1.13 1.12 1.12 .91 1.02
KLA/ATP 1.08 .97 1.02 .95 1.01 .96 1.05
Itgav
KLA  ATP  ATP+KLA
 AK171739 activated spleen cDNA, RIKEN full-length enriched library, clone:F830008B15 product:unclassifiable, full insert sequence. [AK171739] KLA 1.04 .97 1.06 .95 1.15 .89 1.11
ATP 1.41 1.54 1.64 2.24 2.74 1.24 1.18
KLA/ATP 1.09 1.07 1.03 1.01 1.72 1.24 1.10
Itgav
KLA  ATP  ATP+KLA
 NM_008402 integrin alpha V (Itgav), mRNA [NM_008402] KLA 4.00 3.99 3.28 2.24 1.57 .95 1.13
ATP 1.14 1.22 1.13 1.39 2.22 2.47 1.70
KLA/ATP 4.59 4.61 2.48 2.44 1.60 1.88 2.56
Itgax
KLA  ATP  ATP+KLA
 AK089167 NOD-derived CD11c +ve dendritic cells cDNA, RIKEN full-length enriched library, clone:F630002M04 product:integrin alpha X, full insert sequence. [AK089167] KLA 1.07 1.10 1.11 1.08 1.01 1.08 .92
ATP .97 .99 1.09 1.23 1.01 1.00 1.25
KLA/ATP 1.05 1.11 1.09 1.13 1.05 1.01 1.02
Itgax
KLA  ATP  ATP+KLA
 NM_021334 integrin alpha X (Itgax), mRNA [NM_021334] KLA .89 .92 .92 .89 .75 .52 .28
ATP 1.03 1.02 1.18 1.16 1.01 .74 .49
KLA/ATP .97 1.01 1.13 1.10 .86 .64 .42
Itgb1
KLA  ATP  ATP+KLA
 NM_010578 integrin beta 1 (fibronectin receptor beta) (Itgb1), mRNA [NM_010578] KLA 1.05 1.09 1.13 .92 1.01 .93 .88
ATP 1.14 1.30 .92 1.07 1.04 .83 .70
KLA/ATP 1.26 1.30 .87 1.02 .66 .65 .62
Itgb1
KLA  ATP  ATP+KLA
 U37029 integrin beta1D mRNA, partial cds. [U37029] KLA .93 .95 .96 1.01 .97 1.01 .98
ATP 1.05 .99 .99 1.03 1.03 .97 .94
KLA/ATP .99 .98 1.04 .97 1.02 1.01 .99
Itgb2
KLA  ATP  ATP+KLA
 NM_008404 integrin beta 2 (Itgb2), mRNA [NM_008404] KLA .78 .78 .97 .74 1.04 .94 1.14
ATP 1.24 1.23 .79 .95 1.12 .84 1.10
KLA/ATP .99 1.01 .60 .83 .78 .73 .99
Itgb2l
KLA  ATP  ATP+KLA
 NM_008405 integrin beta 2-like (Itgb2l), mRNA [NM_008405] KLA .87 .98 .98 1.00 1.05 1.07 1.10
ATP 1.24 1.23 1.13 1.14 1.29 1.05 1.05
KLA/ATP 1.02 1.08 1.08 1.06 .98 .93 .95
Itgb3
KLA  ATP  ATP+KLA
 AF026509 integrin beta3 subunit mRNA, complete cds. [AF026509] KLA 2.38 2.64 2.65 3.15 4.02 4.46 2.83
ATP 1.21 1.17 1.25 1.62 2.33 3.09 4.78
KLA/ATP 2.48 2.63 3.39 3.72 4.30 4.71 6.79
Itgb3
KLA  ATP  ATP+KLA
 NM_016780 integrin beta 3 (Itgb3), mRNA [NM_016780] KLA .50 .51 .52 .41 .31 .25 .15
ATP .94 .88 1.17 .89 .99 1.36 .91
KLA/ATP .51 .54 .67 .52 .61 .74 .48
Itgb4
KLA  ATP  ATP+KLA
 AK048888 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230078O20 product:integrin beta 4, full insert sequence. [AK048888] KLA .98 .92 .98 1.08 .97 1.02 1.02
ATP .99 .99 .91 1.03 1.02 1.00 1.05
KLA/ATP .99 1.03 .99 .98 .94 .98 1.01
Itgb4
KLA  ATP  ATP+KLA
 NM_001005608 integrin beta 4 (Itgb4), transcript variant 1, mRNA [NM_001005608] KLA 1.09 1.11 1.12 1.08 .98 .86 .85
ATP .90 .89 .90 .95 .87 .87 .84
KLA/ATP 1.06 1.08 1.10 1.18 1.07 .90 .76
Itgb5
KLA  ATP  ATP+KLA
 NM_010580 integrin beta 5 (Itgb5), mRNA [NM_010580] KLA .72 .68 .67 .66 .54 .43 .36
ATP 1.09 .94 .78 .57 .63 .56 .62
KLA/ATP .78 .64 .67 .51 .64 .67 .38
Itgb6
KLA  ATP  ATP+KLA
 NM_021359 integrin beta 6 (Itgb6), mRNA [NM_021359] KLA .97 1.02 1.04 1.06 1.06 1.04 1.01
ATP .99 1.00 1.01 .96 1.04 1.00 1.00
KLA/ATP .99 1.03 1.08 1.02 1.02 1.03 1.01
Itgb7
KLA  ATP  ATP+KLA
 NM_013566 integrin beta 7 (Itgb7), mRNA [NM_013566] KLA .91 .88 .93 1.19 .93 .76 .79
ATP 1.00 .96 1.30 1.44 2.84 3.07 7.90
KLA/ATP .96 1.05 1.35 1.20 2.70 3.53 8.17
Itgb8
KLA  ATP  ATP+KLA
 AK029281 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4832412O06 product:SIMILAR TO INTEGRIN, BETA 8 homolog [Homo sapiens], full insert sequence. [AK029281] KLA 4.66 5.00 3.59 2.70 1.76 1.34 1.32
ATP 1.01 .98 1.09 1.16 2.15 5.24 1.17
KLA/ATP 5.59 6.39 4.38 1.99 1.84 2.55 2.11
Itgb8
KLA  ATP  ATP+KLA
 AK034644 12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430018C17 product:integrin beta 8, full insert sequence. [AK034644] KLA 1.18 1.02 1.04 1.03 1.05 .94 .93
ATP .96 .97 .97 .96 .90 1.04 .99
KLA/ATP 1.06 1.06 1.15 .92 .99 1.00 1.09
Itgb8
KLA  ATP  ATP+KLA
 AK140969 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130086L01 product:hypothetical protein, full insert sequence [AK140969] KLA 3.63 3.76 4.16 3.31 2.72 1.58 1.40
ATP .98 1.01 1.31 1.14 1.28 6.11 1.65
KLA/ATP 3.84 4.18 3.75 2.83 1.92 3.44 4.81
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
LOC10004
8021
KLA  ATP  ATP+KLA
 XM_001479354 ref|PREDICTED: Mus musculus similar to Guanine nucleotide-binding protein alpha-12 subunit (G alpha-12) (LOC100048021), mRNA [XM_001479354] KLA .29 .29 .23 .19 .25 .43 .47
ATP 1.03 1.08 .94 .88 .78 .52 .59
KLA/ATP .32 .29 .20 .22 .31 .47 .36
Limk1
KLA  ATP  ATP+KLA
 NM_010717 LIM-domain containing, protein kinase (Limk1), mRNA [NM_010717] KLA .56 .57 .51 .67 .79 .93 .98
ATP .95 .88 .92 .75 1.01 .86 .88
KLA/ATP .53 .52 .56 .49 .90 .84 .51
Limk2
KLA  ATP  ATP+KLA
 NM_010718 LIM motif-containing protein kinase 2 (Limk2), transcript variant 1, mRNA [NM_010718] KLA .69 .73 .79 .92 1.12 1.18 .97
ATP 1.09 1.05 1.02 .90 .70 .93 1.15
KLA/ATP .78 .76 .77 .69 .71 1.07 1.42
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Map2k2
KLA  ATP  ATP+KLA
 NM_023138 mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] KLA .96 1.01 1.09 .99 1.11 1.15 1.42
ATP 1.07 1.05 .74 .86 1.04 1.16 1.21
KLA/ATP 1.14 1.03 .68 .78 .85 1.01 1.20
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mm.13157
2
KLA  ATP  ATP+KLA
 134949023 Unknown KLA 1.04 1.01 .96 .95 .95 1.00 .99
ATP .98 1.02 .99 1.07 .97 .96 1.00
KLA/ATP .96 .88 .91 1.00 1.02 .98 1.05
Mm.19309
9
KLA  ATP  ATP+KLA
 46849811 Unknown KLA 1.32 1.36 1.42 1.17 1.06 .90 .58
ATP .98 1.12 1.41 1.81 1.44 1.14 .89
KLA/ATP 1.39 1.55 1.57 2.02 1.43 1.12 .74
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.22094
6
KLA  ATP  ATP+KLA
 27545180 Unknown KLA 1.00 .93 .97 1.05 1.06 1.29 1.13
ATP .90 .94 1.25 1.18 .85 .62 1.20
KLA/ATP .86 .99 1.14 .99 .83 .70 1.26
Mm.24060
7
KLA  ATP  ATP+KLA
 162951825 Unknown KLA .94 .96 .91 1.02 .90 .84 .97
ATP 1.08 1.01 1.08 .95 1.04 .89 .89
KLA/ATP .93 1.01 1.05 .92 .84 .88 .76
Mm.24185
7
KLA  ATP  ATP+KLA
 142347489 Unknown KLA 1.18 1.09 1.27 1.24 1.14 1.18 1.15
ATP 1.10 1.02 1.13 1.16 1.04 1.03 1.11
KLA/ATP 1.17 1.19 1.29 1.21 1.10 1.02 1.19
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.26132
9
KLA  ATP  ATP+KLA
 71037402 Unknown KLA 1.53 1.44 1.59 1.66 1.72 1.88 1.09
ATP 1.08 .98 1.38 1.35 1.28 1.25 1.07
KLA/ATP 1.49 1.53 1.97 1.61 1.54 1.25 1.08
Mm.27604
2
KLA  ATP  ATP+KLA
 18702319 Unknown KLA .81 .72 .70 .70 .54 .54 .67
ATP .90 .95 1.17 1.15 1.35 1.32 1.13
KLA/ATP .70 .78 .89 .83 1.09 1.13 .97
Mm.27682
6
KLA  ATP  ATP+KLA
 126513132 Unknown KLA .74 .69 .83 .96 .93 .97 1.21
ATP .71 .66 .60 .75 .88 .90 .79
KLA/ATP .63 .57 .63 .72 .89 .99 .90
Mm.29018
2
KLA  ATP  ATP+KLA
 51921284 Unknown KLA .80 .75 .79 .87 .86 .96 .92
ATP .93 .94 1.07 1.07 1.77 1.52 1.50
KLA/ATP .74 .71 .76 .87 1.61 1.64 1.53
Mm.33981
2
KLA  ATP  ATP+KLA
 6679780 Unknown KLA 1.10 1.14 1.09 1.05 1.05 1.08 1.01
ATP .95 1.06 2.35 11.15 2.46 1.50 1.03
KLA/ATP 1.02 1.05 2.05 8.78 2.65 1.76 1.02
Mm.37161
0
KLA  ATP  ATP+KLA
 118130576 Unknown KLA .76 .74 .66 .81 .74 1.00 .92
ATP .95 .85 1.03 .71 .79 1.32 1.10
KLA/ATP .69 .70 .67 .53 .84 1.50 1.48
Mm.38878
KLA  ATP  ATP+KLA
 118344443 Unknown KLA .94 .85 1.03 .88 .97 .89 .90
ATP 1.25 1.21 1.08 1.11 .67 .82 .28
KLA/ATP .99 .97 .89 .99 .69 .84 .39
Mm.38968
2
KLA  ATP  ATP+KLA
 146198760 Unknown KLA 1.12 1.17 1.21 1.56 1.87 2.15 1.93
ATP 1.05 1.01 1.09 1.17 1.81 3.03 3.81
KLA/ATP 1.27 1.22 1.16 1.32 2.03 3.85 6.75
Mm.45157
8
KLA  ATP  ATP+KLA
 124486802 Unknown KLA .91 1.00 .99 .96 1.05 .99 1.02
ATP .96 1.06 1.02 .95 1.02 1.02 .97
KLA/ATP 1.06 1.00 1.04 1.01 .97 .94 1.05
Mm.46514
KLA  ATP  ATP+KLA
 114326498 Unknown KLA 1.06 .98 1.04 .98 1.00 .99 .99
ATP 1.03 .95 1.00 .93 1.00 1.00 .98
KLA/ATP 1.06 .99 .94 .95 .90 .91 1.02
Mm.47526
5
KLA  ATP  ATP+KLA
 145046272 Unknown KLA 1.05 .97 .80 .91 .84 .88 .82
ATP .96 .81 1.14 .73 .64 1.00 .85
KLA/ATP .91 .89 .98 .66 .67 .78 .64
Mm.5055
KLA  ATP  ATP+KLA
 145966820 Unknown KLA 1.04 .96 1.04 .97 1.00 1.00 .97
ATP .95 .97 .96 .95 .97 .97 .98
KLA/ATP .88 1.04 1.07 1.02 .97 .98 .96
Mos
KLA  ATP  ATP+KLA
 NM_020021 Moloney sarcoma oncogene (Mos), mRNA [NM_020021] KLA 1.14 1.04 1.00 .98 1.09 .94 .98
ATP 1.00 1.01 1.03 1.05 .92 1.04 1.12
KLA/ATP .97 .96 1.04 1.03 .95 .99 1.03
Mras
KLA  ATP  ATP+KLA
 NM_008624 muscle and microspikes RAS (Mras), mRNA [NM_008624] KLA .77 .76 .75 .84 .92 .87 1.35
ATP 1.02 1.00 1.11 1.14 .87 .79 .80
KLA/ATP .77 .77 .86 .78 .69 .63 .61
Msn
KLA  ATP  ATP+KLA
 NM_010833 moesin (Msn), mRNA [NM_010833] KLA 1.50 1.65 1.89 1.55 1.91 1.89 1.87
ATP 1.12 1.47 .86 1.52 1.07 1.00 1.33
KLA/ATP 1.76 2.01 1.10 2.07 .92 1.16 1.66
Myh10
KLA  ATP  ATP+KLA
 NM_175260 myosin, heavy polypeptide 10, non-muscle (Myh10), mRNA [NM_175260] KLA 1.04 1.08 1.24 1.13 1.13 1.02 .77
ATP 1.06 1.09 1.04 1.04 .94 .84 .79
KLA/ATP 1.09 1.16 1.08 1.05 1.05 .88 .75
Myh14
KLA  ATP  ATP+KLA
 NM_028021 myosin, heavy polypeptide 14 (Myh14), mRNA [NM_028021] KLA 1.10 1.12 1.05 1.07 1.10 1.06 1.07
ATP 1.02 1.04 1.03 1.02 1.01 1.04 1.10
KLA/ATP 1.02 1.07 1.06 1.04 1.13 1.10 1.13
Myh9
KLA  ATP  ATP+KLA
 NM_022410 myosin, heavy polypeptide 9, non-muscle (Myh9), transcript variant 1, mRNA [NM_022410] KLA .69 .65 .55 .57 .70 1.14 .82
ATP .91 .98 1.08 .80 .77 .99 .84
KLA/ATP .62 .66 .69 .49 .47 .54 .70
Myl2
KLA  ATP  ATP+KLA
 NM_010861 myosin, light polypeptide 2, regulatory, cardiac, slow (Myl2), mRNA [NM_010861] KLA .88 .93 .94 .95 .94 .77 .60
ATP .96 1.04 1.14 1.06 1.00 .93 .66
KLA/ATP .91 .85 1.07 1.03 .88 .79 .67
Myl7
KLA  ATP  ATP+KLA
 NM_022879 myosin, light polypeptide 7, regulatory (Myl7), mRNA [NM_022879] KLA .95 1.01 1.02 .97 1.00 1.04 1.01
ATP 1.01 1.02 .96 .98 1.00 .98 1.01
KLA/ATP .98 1.06 1.03 .97 .85 1.01 1.00
Mylc2b
KLA  ATP  ATP+KLA
 NM_023402 myosin light chain, regulatory B (Mylc2b), mRNA [NM_023402] KLA .88 .84 .82 .86 .84 1.03 1.08
ATP .97 1.02 1.12 1.24 .96 .83 1.23
KLA/ATP .84 .83 .87 .97 .86 .91 1.34
Mylc2pl
KLA  ATP  ATP+KLA
 NM_021611 myosin light chain 2, precursor lymphocyte-specific (Mylc2pl), transcript variant 1, mRNA [NM_021611] KLA .99 .97 .93 1.05 1.00 1.03 1.00
ATP .99 1.01 1.03 1.03 .98 .97 1.06
KLA/ATP .97 1.03 .93 1.01 .97 1.05 1.05
Mylk
KLA  ATP  ATP+KLA
 AK044527 adult retina cDNA, RIKEN full-length enriched library, clone:A930019C19 product:MYOSIN LIGHT CHAIN KINASE (FRAGMENT) homolog [Mus musculus], full insert sequence. [AK044527] KLA 1.10 .99 .93 1.01 1.00 1.07 1.01
ATP 1.02 .97 .92 .99 1.02 .97 1.06
KLA/ATP 1.01 1.03 1.05 .97 .91 1.00 .96
Mylk
KLA  ATP  ATP+KLA
 NM_139300 myosin, light polypeptide kinase (Mylk), mRNA [NM_139300] KLA 1.05 1.15 1.22 1.24 1.33 1.21 .50
ATP 1.05 1.08 .96 .91 .79 .71 .40
KLA/ATP 1.14 1.18 1.15 1.04 .90 .79 .48
Mylk2
KLA  ATP  ATP+KLA
 NM_001081044 myosin, light polypeptide kinase 2, skeletal muscle (Mylk2), mRNA [NM_001081044] KLA 1.17 1.21 1.11 1.25 1.17 1.10 1.06
ATP .94 1.05 1.06 1.10 1.33 1.33 1.27
KLA/ATP 1.15 1.25 1.14 1.21 1.32 1.29 1.45
Mylk3
KLA  ATP  ATP+KLA
 AK052858 16 days neonate heart cDNA, RIKEN full-length enriched library, clone:D830007F02 product:Weakly similar to myosin light chain kinase, full insert sequence. [AK052858] KLA 1.06 1.02 .95 .98 1.01 1.04 1.02
ATP 1.02 1.06 1.00 1.01 .97 1.01 .98
KLA/ATP 1.08 1.00 .94 1.13 1.07 1.08 1.05
Mylpf
KLA  ATP  ATP+KLA
 NM_016754 myosin light chain, phosphorylatable, fast skeletal muscle (Mylpf), mRNA [NM_016754] KLA 1.07 1.12 1.08 1.20 1.17 1.27 1.34
ATP 1.00 .90 .98 1.08 .98 1.22 1.09
KLA/ATP 1.00 1.15 1.14 1.18 1.18 1.04 1.19
Nckap1
KLA  ATP  ATP+KLA
 NM_016965 NCK-associated protein 1 (Nckap1), mRNA [NM_016965] KLA .99 1.08 1.01 .98 .80 .87 1.25
ATP 1.07 1.18 .94 1.01 .82 1.16 .99
KLA/ATP 1.08 1.11 .77 .98 .76 1.01 1.18
Nckap1l
KLA  ATP  ATP+KLA
 NM_153505 NCK associated protein 1 like (Nckap1l), mRNA [NM_153505] KLA 1.08 .98 .98 .97 1.02 1.24 1.18
ATP .93 .94 1.01 .74 .71 .81 1.26
KLA/ATP .94 1.00 .94 .68 .62 .77 1.44
Nras
KLA  ATP  ATP+KLA
 NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Pak1
KLA  ATP  ATP+KLA
 NM_011035 p21 (CDKN1A)-activated kinase 1 (Pak1), mRNA [NM_011035] KLA .72 .77 .79 .71 .67 .73 .95
ATP 1.10 1.07 .99 1.15 1.27 .62 .51
KLA/ATP .85 .83 .73 .76 .76 .55 .33
Pak2
KLA  ATP  ATP+KLA
 NM_177326 p21 (CDKN1A)-activated kinase 2 (Pak2), mRNA [NM_177326] KLA 1.23 1.24 1.26 1.17 1.19 1.09 1.13
ATP 1.04 1.01 .65 .58 .82 1.18 1.45
KLA/ATP 1.26 1.26 .78 .72 .71 .95 1.44
Pak3
KLA  ATP  ATP+KLA
 NM_008778 p21 (CDKN1A)-activated kinase 3 (Pak3), mRNA [NM_008778] KLA 1.06 1.02 1.03 1.00 1.06 1.01 1.01
ATP 1.05 1.01 1.03 .97 .98 1.08 1.07
KLA/ATP 1.00 .99 .99 1.03 1.00 1.01 1.08
Pak4
KLA  ATP  ATP+KLA
 NM_027470 p21 (CDKN1A)-activated kinase 4 (Pak4), mRNA [NM_027470] KLA 1.41 1.51 1.62 1.57 1.88 1.26 1.06
ATP 1.13 1.15 1.04 1.21 1.73 1.45 1.03
KLA/ATP 1.58 1.60 1.31 1.65 1.84 1.64 1.40
Pak6
KLA  ATP  ATP+KLA
 AK028788 10 days neonate skin cDNA, RIKEN full-length enriched library, clone:4732456M09 product:p21 (CDKN1A)-activated kinase 6, full insert sequence. [AK028788] KLA 1.38 1.33 1.40 1.45 1.42 1.49 1.20
ATP .95 .93 1.15 1.21 1.21 1.32 1.10
KLA/ATP 1.33 1.38 1.55 1.44 1.57 1.45 1.36
Pak7
KLA  ATP  ATP+KLA
 AK077967 13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030481C12 product:hypothetical protein, full insert sequence. [AK077967] KLA 1.00 1.01 1.07 1.02 .99 1.01 1.05
ATP .93 .95 1.03 1.01 1.02 .92 1.00
KLA/ATP 1.04 1.01 .99 1.04 .99 1.06 1.02
Pdgfa
KLA  ATP  ATP+KLA
 NM_008808 platelet derived growth factor, alpha (Pdgfa), mRNA [NM_008808] KLA .63 .56 .42 .34 .31 .33 .52
ATP .89 .80 .69 1.23 5.97 3.99 2.73
KLA/ATP .64 .53 .43 .77 3.48 3.78 2.37
Pdgfb
KLA  ATP  ATP+KLA
 NM_011057 platelet derived growth factor, B polypeptide (Pdgfb), mRNA [NM_011057] KLA .45 .43 .38 .46 .69 .48 .58
ATP .94 .95 .66 .74 .67 .77 1.06
KLA/ATP .43 .43 .37 .39 .52 .55 1.64
Pdgfc
KLA  ATP  ATP+KLA
 AK081347 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130008P20 product:platelet-derived growth factor, C polypeptide, full insert sequence. [AK081347] KLA .93 1.07 1.00 1.03 .93 .95 .98
ATP 1.05 1.04 .94 1.02 1.04 1.00 1.05
KLA/ATP 1.06 1.02 .99 .96 .99 1.05 1.01
Pdgfc
KLA  ATP  ATP+KLA
 NM_019971 platelet-derived growth factor, C polypeptide (Pdgfc), mRNA [NM_019971] KLA 1.56 1.52 1.84 2.08 1.83 1.33 .79
ATP .98 .91 .86 .91 .78 1.43 3.28
KLA/ATP 1.45 1.50 1.25 1.73 1.99 1.56 1.12
Pdgfd
KLA  ATP  ATP+KLA
 AK141551 adult male hippocampus cDNA, RIKEN full-length enriched library, clone:C630020I23 product:platelet-derived growth factor, D polypeptide, full insert sequence [AK141551] KLA 1.07 1.01 1.06 .98 .94 1.00 1.00
ATP .98 .99 1.10 1.00 .96 1.00 .94
KLA/ATP 1.00 1.03 1.05 1.02 .94 .97 1.03
Pdgfd
KLA  ATP  ATP+KLA
 NM_027924 platelet-derived growth factor, D polypeptide (Pdgfd), mRNA [NM_027924] KLA .99 .93 .95 .97 1.00 .99 .95
ATP 1.01 .99 1.00 .93 1.05 1.04 1.06
KLA/ATP .91 .91 .96 .92 .92 .99 1.05
Pdgfra
KLA  ATP  ATP+KLA
 NM_011058 platelet derived growth factor receptor, alpha polypeptide (Pdgfra), transcript variant 1, mRNA [NM_011058] KLA 1.02 1.05 1.02 1.01 1.03 1.03 1.01
ATP 1.01 1.02 1.03 1.04 1.00 1.01 1.01
KLA/ATP 1.01 1.01 .99 1.03 1.02 1.03 1.01
Pdgfrb
KLA  ATP  ATP+KLA
 NM_008809 platelet derived growth factor receptor, beta polypeptide (Pdgfrb), mRNA [NM_008809] KLA 4.85 5.49 4.56 3.94 3.71 2.05 1.51
ATP .99 1.00 1.11 1.27 1.02 1.83 1.23
KLA/ATP 5.09 5.86 4.30 2.51 1.74 1.84 3.23
Pfn1
KLA  ATP  ATP+KLA
 NM_011072 profilin 1 (Pfn1), mRNA [NM_011072] KLA .83 1.00 .95 .82 .96 1.18 1.41
ATP 1.21 1.60 .75 1.78 1.08 .72 1.09
KLA/ATP 1.27 1.22 .45 1.61 .70 1.00 1.18
Pfn2
KLA  ATP  ATP+KLA
 NM_019410 profilin 2 (Pfn2), mRNA [NM_019410] KLA .92 .86 .85 .87 .87 .83 1.02
ATP 1.02 1.06 .99 .95 .83 .96 .90
KLA/ATP .88 .89 .92 .83 .76 .81 .98
Pfn3
KLA  ATP  ATP+KLA
 NM_029303 profilin 3 (Pfn3), mRNA [NM_029303] KLA 1.02 .94 .93 .93 .98 .98 .99
ATP 1.06 .95 1.05 .92 .98 .91 1.04
KLA/ATP 1.04 .92 1.04 .95 1.03 .92 1.05
Pfn4
KLA  ATP  ATP+KLA
 NM_028376 profilin family, member 4 (Pfn4), mRNA [NM_028376] KLA 1.03 1.02 .94 .92 .94 .91 .98
ATP 1.05 1.03 1.05 .93 .97 1.00 .94
KLA/ATP 1.05 .95 .94 .89 .90 .88 .90
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Pip4k2a
KLA  ATP  ATP+KLA
 NM_008845 phosphatidylinositol-5-phosphate 4-kinase, type II, alpha (Pip4k2a), mRNA [NM_008845] KLA .56 .55 .57 .71 .81 .75 .73
ATP .98 1.04 .92 1.19 .99 .74 .59
KLA/ATP .55 .55 .50 .58 .60 .59 .76
Pip4k2b
KLA  ATP  ATP+KLA
 AB054987 pipk type II beta mRNA for Phosphatidyl inositol phosphate kinase type II beta, partial cds. [AB054987] KLA 1.09 1.03 1.08 1.13 1.07 1.00 .92
ATP 1.14 .98 .98 1.01 1.16 1.18 .93
KLA/ATP 1.00 1.08 1.06 1.04 1.16 1.09 1.07
Pip4k2b
KLA  ATP  ATP+KLA
 NM_054051 phosphatidylinositol-5-phosphate 4-kinase, type II, beta (Pip4k2b), mRNA [NM_054051] KLA .45 .47 .40 .50 .73 1.06 1.14
ATP 1.00 1.04 1.02 .85 .60 .63 .73
KLA/ATP .46 .45 .41 .44 .54 .54 .42
Pip4k2c
KLA  ATP  ATP+KLA
 NM_054097 phosphatidylinositol-5-phosphate 4-kinase, type II, gamma (Pip4k2c), mRNA [NM_054097] KLA .65 .65 .67 .71 .79 .88 .95
ATP 1.01 1.01 .90 .84 1.27 1.48 1.33
KLA/ATP .63 .65 .57 .53 1.09 1.50 1.44
Pip5k1a
KLA  ATP  ATP+KLA
 NM_008847 phosphatidylinositol-4-phosphate 5-kinase, type 1 alpha (Pip5k1a), mRNA [NM_008847] KLA 1.99 1.84 1.66 1.49 1.49 1.37 1.57
ATP 1.05 1.06 .89 1.54 4.20 2.72 1.58
KLA/ATP 1.95 1.90 1.55 1.60 3.26 2.64 2.25
Pip5k1b
KLA  ATP  ATP+KLA
 NM_008846 phosphatidylinositol-4-phosphate 5-kinase, type 1 beta (Pip5k1b), mRNA [NM_008846] KLA 1.24 1.35 1.11 .92 .57 .72 .86
ATP .86 1.00 .96 1.15 .85 .74 .89
KLA/ATP 1.20 1.22 .97 1.00 .78 .76 1.06
Pip5k1c
KLA  ATP  ATP+KLA
 BC094665 phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma, mRNA (cDNA clone MGC:102155 IMAGE:30356181), complete cds [BC094665] KLA .82 .90 .90 .70 .96 .86 1.21
ATP 1.19 1.45 .92 1.64 1.17 .83 1.33
KLA/ATP .97 1.21 .66 1.20 .91 .92 1.69
Pip5k1c
KLA  ATP  ATP+KLA
 NM_008844 phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma (Pip5k1c), mRNA [NM_008844] KLA 1.40 1.36 1.38 1.39 1.30 1.30 1.27
ATP 1.01 1.16 1.12 1.46 1.38 1.35 1.21
KLA/ATP 1.39 1.44 1.44 1.64 1.41 1.45 1.53
Pip5k3
KLA  ATP  ATP+KLA
 NM_011086 phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase, type III (Pip5k3), mRNA [NM_011086] KLA 2.92 2.86 2.69 1.86 1.49 1.25 1.14
ATP 1.15 1.23 1.19 1.19 1.63 1.06 1.18
KLA/ATP 3.09 3.42 2.64 2.17 1.71 1.25 1.14
Ppp1ca
KLA  ATP  ATP+KLA
 NM_031868 protein phosphatase 1, catalytic subunit, alpha isoform (Ppp1ca), mRNA [NM_031868] KLA .89 .93 .93 .86 .95 1.07 1.20
ATP 1.04 1.07 .93 1.02 1.01 .89 1.10
KLA/ATP .98 .93 .74 .91 .84 1.01 1.34
Ppp1cb
KLA  ATP  ATP+KLA
 NM_172707 protein phosphatase 1, catalytic subunit, beta isoform (Ppp1cb), mRNA [NM_172707] KLA 1.12 1.08 1.05 1.02 .89 .84 .94
ATP .89 .87 .75 .55 .73 1.14 .69
KLA/ATP .92 .94 .80 .64 .64 .83 .65
Ppp1cc
KLA  ATP  ATP+KLA
 NM_013636 protein phosphatase 1, catalytic subunit, gamma isoform (Ppp1cc), mRNA [NM_013636] KLA .51 .51 .49 .48 .53 .64 .64
ATP 1.02 1.01 .85 .79 .72 .89 .95
KLA/ATP .54 .49 .42 .43 .56 .76 .81
Ppp1r12a
KLA  ATP  ATP+KLA
 AK077739 8 days embryo whole body cDNA, RIKEN full-length enriched library, clone:5730577I22 product:inferred: myosin phosphatase, target subunit 1, full insert sequence [AK077739] KLA 1.91 1.98 2.00 2.00 1.63 1.58 1.17
ATP .93 .80 .82 .46 1.01 1.29 .79
KLA/ATP 1.82 1.80 1.85 .91 1.54 1.51 .90
Ppp1r12a
KLA  ATP  ATP+KLA
 NM_027892 protein phosphatase 1, regulatory (inhibitor) subunit 12A (Ppp1r12a), mRNA [NM_027892] KLA 2.36 2.42 2.34 2.71 1.96 2.11 1.93
ATP .87 .85 1.00 .98 1.75 4.57 2.89
KLA/ATP 2.02 2.24 2.59 1.90 2.16 4.01 5.77
Ppp1r12b
KLA  ATP  ATP+KLA
 AK132310 15 days embryo head cDNA, RIKEN full-length enriched library, clone:4022402N03 product:unclassifiable, full insert sequence [AK132310] KLA .82 .86 .71 .94 1.26 1.84 5.38
ATP 1.02 1.07 1.17 1.23 1.24 1.58 1.53
KLA/ATP .83 .82 .82 .84 .80 1.51 3.05
Ppp1r12b
KLA  ATP  ATP+KLA
 NM_001081307 protein phosphatase 1, regulatory (inhibitor) subunit 12B (Ppp1r12b), mRNA [NM_001081307] KLA .78 .80 .80 .75 .85 .79 .91
ATP .87 .83 .89 .75 1.01 .88 1.04
KLA/ATP .74 .73 .78 .71 .88 .86 .89
Ptk2
KLA  ATP  ATP+KLA
 NM_007982 PTK2 protein tyrosine kinase 2 (Ptk2), mRNA [NM_007982] KLA .99 .99 1.02 1.04 1.09 1.22 1.57
ATP 1.04 1.09 .95 .98 .67 .96 .87
KLA/ATP .99 1.03 .87 .93 .81 1.16 1.04
Pxn
KLA  ATP  ATP+KLA
 AK084243 12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230012N01 product:inferred: paxillin beta {Homo sapiens}, full insert sequence. [AK084243] KLA 1.06 .92 1.01 .95 .97 .97 1.02
ATP 1.02 1.02 .97 .90 .98 .94 .89
KLA/ATP .96 .97 .98 .91 1.01 1.00 .94
Pxn
KLA  ATP  ATP+KLA
 NM_133915 paxillin (Pxn), transcript variant beta, mRNA [NM_133915] KLA 1.13 1.13 1.14 1.14 1.49 1.60 1.30
ATP 1.11 1.22 .86 1.04 1.14 1.18 1.35
KLA/ATP 1.41 1.22 .80 .92 1.07 1.54 2.60
Rac1
KLA  ATP  ATP+KLA
 NM_009007 RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] KLA 1.02 1.01 1.02 .99 1.03 1.15 1.08
ATP .99 1.15 1.01 1.27 1.06 1.20 1.06
KLA/ATP 1.00 1.04 .88 1.16 .91 1.21 1.38
Rac2
KLA  ATP  ATP+KLA
 NM_009008 RAS-related C3 botulinum substrate 2 (Rac2), mRNA [NM_009008] KLA 1.55 1.68 1.86 2.15 3.36 3.59 3.74
ATP 1.13 1.16 .74 .99 .84 .91 1.66
KLA/ATP 1.59 1.71 1.19 1.56 1.21 1.60 3.48
Rac3
KLA  ATP  ATP+KLA
 NM_133223 RAS-related C3 botulinum substrate 3 (Rac3), mRNA [NM_133223] KLA 2.03 2.20 2.64 2.18 2.95 2.29 1.41
ATP 1.02 1.12 .94 1.42 1.16 .84 .87
KLA/ATP 2.30 2.32 1.57 2.55 1.75 1.47 1.61
Raf1
KLA  ATP  ATP+KLA
 AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
 NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Rdx
KLA  ATP  ATP+KLA
 AK085332 0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630012L19 product:unclassifiable, full insert sequence [AK085332] KLA .97 .94 .92 .94 .91 .97 .93
ATP .97 .94 .99 1.03 .94 .99 .91
KLA/ATP .93 1.00 .96 .95 .90 .91 .90
Rdx
KLA  ATP  ATP+KLA
 NM_009041 radixin (Rdx), transcript variant 1, mRNA [NM_009041] KLA 1.27 1.41 1.40 1.39 1.00 .64 .68
ATP 1.02 1.21 1.02 .99 .82 .89 .63
KLA/ATP 1.38 1.49 1.22 1.25 .88 .77 .79
Rhoa
KLA  ATP  ATP+KLA
 NM_016802 ras homolog gene family, member A (Rhoa), mRNA [NM_016802] KLA .93 1.00 1.07 .97 1.08 1.06 1.02
ATP .93 .88 .49 .61 .63 .78 1.05
KLA/ATP .94 .92 .59 .63 .61 .78 1.12
Rock1
KLA  ATP  ATP+KLA
 NM_009071 Rho-associated coiled-coil containing protein kinase 1 (Rock1), mRNA [NM_009071] KLA 2.40 2.48 2.37 3.07 1.94 1.42 1.21
ATP .95 .92 .87 .70 1.13 1.74 .98
KLA/ATP 2.27 2.35 2.56 1.60 1.65 1.56 1.23
Rock2
KLA  ATP  ATP+KLA
 NM_009072 Rho-associated coiled-coil containing protein kinase 2 (Rock2), mRNA [NM_009072] KLA .99 .92 .83 .87 .73 .74 1.04
ATP 1.07 1.31 1.16 1.02 1.02 1.03 .88
KLA/ATP 1.00 1.07 .93 .85 .69 .63 .81
Rras
KLA  ATP  ATP+KLA
 NM_009101 Harvey rat sarcoma oncogene, subgroup R (Rras), mRNA [NM_009101] KLA .89 .89 .99 .98 1.25 1.48 1.81
ATP 1.14 1.17 1.01 1.61 1.37 1.33 1.40
KLA/ATP 1.09 1.05 1.01 1.34 1.24 1.10 1.27
Rras2
KLA  ATP  ATP+KLA
 NM_025846 related RAS viral (r-ras) oncogene homolog 2 (Rras2), mRNA [NM_025846] KLA 7.72 7.35 7.03 5.47 3.21 1.03 .65
ATP .92 .86 .99 .95 1.86 2.13 .72
KLA/ATP 6.51 6.50 5.94 4.45 3.05 1.72 .75
Scin
KLA  ATP  ATP+KLA
 NM_009132 scinderin (Scin), mRNA [NM_009132] KLA 1.23 1.20 1.11 .94 .94 .89 1.22
ATP .99 .96 1.22 1.23 1.62 1.21 1.65
KLA/ATP 1.08 1.26 1.18 1.35 2.00 1.38 1.58
Slc9a1
KLA  ATP  ATP+KLA
 NM_016981 solute carrier family 9 (sodium/hydrogen exchanger), member 1 (Slc9a1), mRNA [NM_016981] KLA 1.74 1.72 1.95 1.84 1.86 1.53 1.49
ATP 1.11 1.28 .95 1.46 1.98 2.67 1.47
KLA/ATP 1.85 2.02 1.70 2.47 2.18 3.18 3.48
Slc9a1
KLA  ATP  ATP+KLA
 U51112 Na+/H+ exchanger (NHE-1) mRNA, complete cds. [U51112] KLA 1.78 1.83 2.11 1.90 1.91 1.61 1.40
ATP 1.07 1.14 .98 1.54 2.00 2.85 1.44
KLA/ATP 1.97 2.16 2.01 2.44 2.30 3.37 3.15
Sos1
KLA  ATP  ATP+KLA
 NM_009231 Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] KLA 2.36 2.40 3.42 3.15 2.78 1.81 1.71
ATP .99 1.00 .99 1.15 1.14 1.25 1.24
KLA/ATP 2.41 2.26 1.95 2.44 1.47 1.66 1.37
Sos2
KLA  ATP  ATP+KLA
 XM_127051 gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] KLA .81 .77 .79 .92 1.04 1.06 1.20
ATP 1.00 1.00 1.09 .79 .68 .81 .94
KLA/ATP .77 .69 .71 .60 .64 .77 1.07
Src
KLA  ATP  ATP+KLA
 NM_009271 Rous sarcoma oncogene (Src), transcript variant 1, mRNA [NM_009271] KLA 6.99 7.23 7.54 5.99 5.34 3.39 3.00
ATP 1.02 1.06 1.06 2.08 4.41 5.03 3.97
KLA/ATP 7.44 7.51 5.48 6.24 4.86 5.86 7.90
Ssh1
KLA  ATP  ATP+KLA
 AK173144 mRNA for mKIAA1298 protein [AK173144] KLA 1.09 1.00 1.08 1.67 2.17 2.51 1.79
ATP .94 .86 1.17 .99 2.12 4.72 4.42
KLA/ATP .98 .95 1.20 1.10 3.10 4.68 8.20
Ssh2
KLA  ATP  ATP+KLA
 AK173243 mRNA for mKIAA1725 protein [AK173243] KLA .18 .20 .24 .43 .47 .34 .34
ATP 1.15 1.09 1.04 1.24 .61 .59 .41
KLA/ATP .21 .19 .26 .35 .31 .66 .35
Ssh2
KLA  ATP  ATP+KLA
 NM_177710 slingshot homolog 2 (Drosophila) (Ssh2), mRNA [NM_177710] KLA .40 .43 .48 .79 .71 .58 .62
ATP .92 .99 1.53 1.57 .66 .62 .59
KLA/ATP .39 .40 .59 .74 .51 .78 .61
Ssh3
KLA  ATP  ATP+KLA
 NM_198113 slingshot homolog 3 (Drosophila) (Ssh3), mRNA [NM_198113] KLA 1.38 1.51 1.55 1.64 2.21 1.90 2.33
ATP 1.26 1.44 .75 1.03 .88 .86 1.51
KLA/ATP 1.82 1.71 .87 1.47 .80 .71 2.10
Tiam1
KLA  ATP  ATP+KLA
 NM_009384 T-cell lymphoma invasion and metastasis 1 (Tiam1), mRNA [NM_009384] KLA 1.72 1.71 2.10 1.75 1.43 .71 .27
ATP 1.04 1.03 .79 .88 .90 .72 1.07
KLA/ATP 1.79 1.84 1.46 1.43 .90 .87 .73
Tmsb4x
KLA  ATP  ATP+KLA
 NM_021278 thymosin, beta 4, X chromosome (Tmsb4x), mRNA [NM_021278] KLA 1.02 1.02 1.12 .97 1.15 1.32 1.86
ATP .97 .86 1.12 .77 .86 .81 .62
KLA/ATP .94 .85 1.30 .85 1.01 .79 .43
Vav1
KLA  ATP  ATP+KLA
 NM_011691 vav 1 oncogene (Vav1), mRNA [NM_011691] KLA .79 .83 .98 1.17 1.97 2.42 2.26
ATP 1.06 1.02 .88 1.01 1.34 .82 1.36
KLA/ATP .88 .85 .73 .78 1.25 1.47 2.17
Vav2
KLA  ATP  ATP+KLA
 BC053060 vav 2 oncogene, mRNA (cDNA clone MGC:62363 IMAGE:5704852), complete cds [BC053060] KLA .73 .58 .55 1.16 .76 1.35 1.75
ATP .99 .89 .79 .82 .67 .85 1.09
KLA/ATP .64 .63 .61 .65 .66 .80 1.23
Vav2
KLA  ATP  ATP+KLA
 NM_009500 vav 2 oncogene (Vav2), mRNA [NM_009500] KLA .98 1.05 .98 .99 1.02 1.36 1.43
ATP 1.07 1.06 .96 1.01 .89 .95 1.08
KLA/ATP 1.04 1.05 .98 1.03 .88 .99 1.13
Vav3
KLA  ATP  ATP+KLA
 NM_020505 vav 3 oncogene (Vav3), transcript variant 1, mRNA [NM_020505] KLA .95 .94 .86 .87 .82 .66 .56
ATP 1.06 1.09 .81 1.05 .80 .75 .85
KLA/ATP 1.00 .84 .62 .85 .74 .56 .74
Vcl
KLA  ATP  ATP+KLA
 NM_009502 vinculin (Vcl), mRNA [NM_009502] KLA .88 .97 .87 .70 .73 .69 .70
ATP 1.07 1.25 1.00 1.24 .87 1.17 1.17
KLA/ATP .98 1.02 .72 .98 .58 .71 .88
Was
KLA  ATP  ATP+KLA
 NM_009515 Wiskott-Aldrich syndrome homolog (human) (Was), mRNA [NM_009515] KLA .66 .67 .64 .65 .88 1.08 1.09
ATP 1.08 1.11 .87 1.23 .77 .51 .90
KLA/ATP .76 .70 .44 .83 .49 .61 .91
Wasf1
KLA  ATP  ATP+KLA
 NM_031877 WASP family 1 (Wasf1), mRNA [NM_031877] KLA .75 .69 .77 .81 .69 .66 .54
ATP 1.01 .97 .93 .98 .70 .66 .97
KLA/ATP .75 .73 .80 .79 .73 .67 .56
Wasf2
KLA  ATP  ATP+KLA
 AK150140 bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:G530136J12 product:WAS protein family, member 2, full insert sequence [AK150140] KLA .58 .52 .52 .83 1.06 1.17 .91
ATP .97 .89 .93 .57 .72 .72 .86
KLA/ATP .55 .45 .56 .36 .45 .65 1.08
Wasf2
KLA  ATP  ATP+KLA
 NM_153423 WAS protein family, member 2 (Wasf2), mRNA [NM_153423] KLA .67 .75 .66 1.01 1.31 1.28 1.19
ATP 1.05 1.10 .82 .81 .82 .68 .92
KLA/ATP .75 .76 .73 .57 .61 .77 1.16
Wasl
KLA  ATP  ATP+KLA
 NM_028459 Wiskott-Aldrich syndrome-like (human) (Wasl), mRNA [NM_028459] KLA .88 .89 .96 .85 .97 1.08 1.14
ATP 1.08 .99 .71 .76 1.71 .91 .99
KLA/ATP .96 .84 .72 .84 1.51 .91 1.24